1. Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue.
- Author
-
Rumbaugh G, Daws SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, and Miller CA
- Subjects
- Alzheimer Disease complications, Alzheimer Disease genetics, Amyloid beta-Protein Precursor genetics, Animals, Animals, Newborn, Cells, Cultured, Conditioning, Psychological drug effects, Disease Models, Animal, Fear drug effects, Gene Expression Profiling, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, Histone Deacetylase Inhibitors pharmacology, Humans, Hydroxamic Acids therapeutic use, Memory Disorders etiology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Mutation genetics, Neurons drug effects, Neurons physiology, Presenilin-1 genetics, Synaptophysin genetics, Synaptophysin metabolism, Histone Deacetylase Inhibitors therapeutic use, Histone Deacetylases metabolism, Memory Disorders drug therapy, Memory Disorders pathology, Synapses drug effects
- Abstract
Histone deacetylases (HDACs) are promising therapeutic targets for neurological and psychiatric disorders that impact cognitive ability, but the relationship between various HDAC isoforms and cognitive improvement is poorly understood, particularly in mouse models of memory impairment. A goal shared by many is to develop HDAC inhibitors with increased isoform selectivity in order to reduce unwanted side effects, while retaining procognitive effects. However, studies addressing this tack at the molecular, cellular and behavioral level are limited. Therefore, we interrogated the biological effects of class I HDAC inhibitors with varying selectivity and assessed a subset of these compounds for their ability to regulate transcriptional activity, synaptic function and memory. The HDAC-1, -2, and -3 inhibitors, RGFP963 and RGFP968, were most effective at stimulating synaptogenesis, while the selective HDAC3 inhibitor, RGFP966, with known memory enhancing abilities, had minimal impact. Furthermore, RGFP963 increased hippocampal spine density, while HDAC3 inhibition was ineffective. Genome-wide gene expression analysis by RNA sequencing indicated that RGFP963 and RGFP966 induce largely distinct transcriptional profiles in the dorsal hippocampus of mature mice. The results of bioinformatic analyses were consistent with RGFP963 inducing a transcriptional program that enhances synaptic efficacy. Finally, RGFP963, but not RGFP966, rescued memory in a mouse model of Alzheimer's Disease. Together, these studies suggest that the specific memory promoting properties of class I HDAC inhibitors may depend on isoform selectivity and that certain pathological brain states may be more receptive to HDAC inhibitors that improve network function by enhancing synapse efficacy.
- Published
- 2015
- Full Text
- View/download PDF